The FDA approves a new type of schizophrenia drug

By Sydney Lupkin

Published September 26, 2024 at 4:42 PM EDT

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

Corrected: September 26, 2024 at 5:29 PM EDT

The initial version of this online summary incorrectly stated that the Food and Drug Administration had approved KarXT. The broadcast story reported that the agency was expected to approve the drug soon. The FDA then approved the drug, as expected, and both the summary and broadcast story were updated.

Sydney Lupkin

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

See stories by Sydney Lupkin

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Donate